DMA treatment efficiently impaired the TGF‐β/SMAD signalling activity in cancer cells co‐implanted with CAFs, reducing it to basal levels comparable to those detected in singly implanted MCF7.Gluc cells (Figure 9b), and confirming a major role for EVs in CAF‐induced effects. The gene discussed is TGFB1; the disease is cancer.